文章：

利用程序化协作建立放射性药物诊所

Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic

原文发布日期：2 April 2024

DOI: 10.3390/cancers16071396

类型: Article

开放获取: 是

英文摘要：

Radiation oncologists, radiopharmacists, nuclear medicine physicians, and medical oncologists have seen a renewed clinical interest in radiopharmaceuticals for the curative or the palliative treatment of cancer. To allow for the discovery and the clinical advancement of targeted radiopharmaceuticals, these stakeholders have reformed their trial efforts and remodeled their facilities to accommodate the obligations of a program centered upon radioactive investigational drug products. Now considered informally as drugs and not beam radiotherapy, radiopharmaceuticals can be more easily studied in the traditional clinical trial enterprise ranging from phase 0–I to phase III studies. Resources and physical facilities allocated to radiopharmaceuticals have brought forth new logistics and patient experience for safe and satisfactory drug delivery. The clinical use of theranostic agents—that is, diagnostic and therapeutic radionuclide pairs—has accelerated radiopharmaceutical development.

摘要翻译： 

放射肿瘤学家、放射药剂师、核医学医师以及肿瘤内科医生对放射性药物在癌症根治性或姑息性治疗中的临床应用重新产生了浓厚兴趣。为促进靶向放射性药物的研发与临床进展，相关从业者已调整其临床试验策略并改造设施，以适应以放射性研究性药物为核心的研发要求。如今放射性药物在非正式层面已被视为药物而非射线放疗手段，因而能更便捷地纳入从0-Ⅰ期到Ⅲ期的传统临床试验体系。针对放射性药物配置的资源和实体设施，为安全满意的药物递送带来了全新的物流方案与患者体验。诊疗一体化药物（即诊断性与治疗性放射性核素配对使用）的临床应用，进一步加速了放射性药物的发展进程。

原文链接：

Leveraging Programmatic Collaboration for a Radiopharmaceutical Clinic